• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors.

作者信息

Byun Ja Min, Koh Youngil, Shin Dong-Yeop, Kim Inho, Yoon Sung-Soo, Lee Jeong-Ok, Bang Soo-Mee, Kim Ki Hwan, Jung Sung-Hoon, Lee Won Sik, Park Yong, Jang Jun Ho, Han Jae Joon, Yhim Ho-Young, Kim Dae Sik, Lee Yoo Jin, Lee Hyewon, Choi Yun-Suk, Lee Seok

机构信息

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, Korea.

出版信息

Haematologica. 2017 May;102(5):e187-e190. doi: 10.3324/haematol.2016.159988. Epub 2017 Jan 12.

DOI:10.3324/haematol.2016.159988
PMID:28082339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5477621/
Abstract
摘要

相似文献

1
translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors.在强效酪氨酸激酶抑制剂时代，易位作为老年急性淋巴细胞白血病患者的一个有利预后因素。
Haematologica. 2017 May;102(5):e187-e190. doi: 10.3324/haematol.2016.159988. Epub 2017 Jan 12.
2
Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.将博纳吐单抗与针对BCR-ABL突变的复发/难治性急性淋巴细胞白血病的靶向治疗联合使用。
Leuk Lymphoma. 2018 Aug;59(8):2011-2013. doi: 10.1080/10428194.2017.1411595. Epub 2017 Dec 18.
3
Reaping the benefits of recent advances for adults with acute lymphoblastic leukemia.让成人急性淋巴细胞白血病患者从近期的进展中获益。
J Natl Compr Canc Netw. 2012 Jul 1;10(7):800-1. doi: 10.6004/jnccn.2012.0083.
4
Philadelphia-positive Acute Lymphoblastic Leukemia: Do We Still Need Allogeneic Transplantation? Argument "Pro".费城染色体阳性急性淋巴细胞白血病：我们仍需要异基因移植吗？正方观点。
Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S10-S15. doi: 10.1016/j.clml.2017.03.296.
5
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.BCR-ABL阳性急性淋巴细胞白血病中的酪氨酸激酶抑制剂
Haematologica. 2015 Mar;100(3):295-9. doi: 10.3324/haematol.2015.124016.
6
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.酪氨酸激酶抑制剂时代费城染色体阳性急性淋巴细胞白血病的首次复发。
Am J Hematol. 2019 Dec;94(12):1388-1395. doi: 10.1002/ajh.25648. Epub 2019 Oct 21.
7
[Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].[伊马替尼联合化疗治疗费城染色体/BCR-ABL阳性急性淋巴细胞白血病患者的分子反应及预后因素]
Zhonghua Xue Ye Xue Za Zhi. 2014 Feb;35(2):120-5. doi: 10.3760/cma.j.issn.0253-2727.2014.02.013.
8
Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.成人急性淋巴细胞白血病的表达谱分析确定了一个以高无反应率和复发率为特征的BCR-ABL1样亚组。
Haematologica. 2015 Jul;100(7):e261-4. doi: 10.3324/haematol.2014.117424. Epub 2015 Mar 13.
9
Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.小儿急性淋巴细胞白血病患者接受酪氨酸激酶抑制剂治疗期间出现的BCR/ABL1新突变
Acta Haematol. 2015;134(2):71-5. doi: 10.1159/000371831. Epub 2015 Apr 18.
10
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.三种新型患者源性 BCR/ABL 突变体对第二代和第三代酪氨酸激酶抑制剂表现出不同的敏感性。
Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

引用本文的文献

1
Cryptic to conventional cytogenetics: Philadelphia-like ALL presenting with hypereosinophilia.对传统细胞遗传学来说很隐匿：伴有嗜酸性粒细胞增多的费城样急性淋巴细胞白血病。
BMJ Case Rep. 2025 Jan 21;18(1):e259811. doi: 10.1136/bcr-2024-259811.
2
Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches.重建克隆进化——对当前生物信息学方法的系统评价。
Int J Environ Res Public Health. 2023 Mar 14;20(6):5128. doi: 10.3390/ijerph20065128.
3
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia.老年（>55岁）急性淋巴细胞白血病患者的特征与预后
Cancers (Basel). 2022 Jan 23;14(3):565. doi: 10.3390/cancers14030565.
4
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.针对急性髓系白血病患者循环游离 DNA 与骨髓的靶向下一代测序。
Blood Adv. 2020 Apr 28;4(8):1670-1677. doi: 10.1182/bloodadvances.2019001156.
5
Management of older adults with acute lymphoblastic leukemia: challenges & current approaches.老年急性淋巴细胞白血病的管理：挑战与当前方法
Int J Hematol Oncol. 2018 Apr 10;7(1):IJH02. doi: 10.2217/ijh-2017-0023. eCollection 2018 Mar.
6
Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.老年急性淋巴细胞白血病的新型治疗方法。
Curr Hematol Malig Rep. 2018 Apr;13(2):91-99. doi: 10.1007/s11899-018-0440-3.

本文引用的文献

1
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.接受酪氨酸激酶抑制剂治疗的Ph+急性淋巴细胞白血病患者的BCR-ABL特异性T细胞疗法。
Blood. 2017 Feb 2;129(5):582-586. doi: 10.1182/blood-2016-07-731091. Epub 2016 Dec 7.
2
Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.老年及身体状况良好的急性淋巴细胞白血病老年患者中基于亚型方案的可行性及结果：PETHEMA组三项前瞻性平行试验的结果
Leuk Res. 2016 Feb;41:12-20. doi: 10.1016/j.leukres.2015.11.012. Epub 2015 Dec 2.
3
Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.CDK4/6抑制剂PD0332991对费城染色体阳性淋巴白血病的特异性抗白血病活性
Mol Cancer Ther. 2016 Jan;15(1):94-105. doi: 10.1158/1535-7163.MCT-14-1065. Epub 2015 Dec 4.
4
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.Hyper-CVAD与波纳替尼联合作为费城染色体阳性急性淋巴细胞白血病患者的一线治疗：一项单中心2期研究。
Lancet Oncol. 2015 Nov;16(15):1547-1555. doi: 10.1016/S1470-2045(15)00207-7. Epub 2015 Sep 30.
5
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.一项关于化疗联合达沙替尼用于初治费城染色体阳性急性淋巴细胞白血病患者的2期研究的长期随访
Cancer. 2015 Dec 1;121(23):4158-64. doi: 10.1002/cncr.29646. Epub 2015 Aug 26.
6
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.尼罗替尼联合多种化疗药物治疗初诊费城阳性急性淋巴细胞白血病。
Blood. 2015 Aug 6;126(6):746-56. doi: 10.1182/blood-2015-03-636548. Epub 2015 Jun 11.
7
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia.成人急性淋巴细胞白血病的病理生理学和治疗新见解。
Cancer. 2015 Aug 1;121(15):2517-28. doi: 10.1002/cncr.29383. Epub 2015 Apr 17.
8
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.Ph 阳性急性淋巴细胞白血病成人患者中采用减低强度化疗联合伊马替尼的随机研究。
Blood. 2015 Jun 11;125(24):3711-9. doi: 10.1182/blood-2015-02-627935. Epub 2015 Apr 15.
9
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.甲磺酸伊马替尼联合hyper-CVAD一线治疗成人费城染色体阳性急性淋巴细胞白血病的II期研究最终报告
Haematologica. 2015 May;100(5):653-61. doi: 10.3324/haematol.2014.118588. Epub 2015 Feb 14.
10
Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.用于18至50岁新诊断急性淋巴细胞白血病成人患者的儿童启发式方案的长期结果。
Leukemia. 2015 Mar;29(3):526-34. doi: 10.1038/leu.2014.229. Epub 2014 Jul 31.